Research programme: central nervous system disorder therapeutics - Hua Medicine
Latest Information Update: 15 Mar 2016
At a glance
- Originator Hua Medicine
- Mechanism of Action Metabotropic glutamate receptor 5 modulators
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Depressive disorders; Fragile X syndrome; Parkinson's disease
Most Recent Events
- 12 Jan 2015 Early research in Depressive disorders in China (unspecified route)
- 12 Jan 2015 Early research in Parkinson's disease in China (unspecified route)
- 12 Jan 2015 Early research in Fragile X syndrome in China (unspecified route)